Histone deacetylase (HDAC) inhibitors have emerged as a novel strategy for cancer treatment due to their regulation of epigenetic changes, which play a critical role in tumor development, immune regulation, drug resistance, and recurrence.9,10 One key advantage of HDAC is their relatively lower rate of side effects. Here, HDAC9 is linked to cancer.